Results 131 to 140 of about 25,729 (205)

Short‐Course Low‐Dose Primaquine for Radical Cure in G6PD‐Normal Patients in the Pre‐Elimination Context of Nepal

open access: yesTropical Medicine &International Health, Volume 31, Issue 8, Page 1028-1034, August 2026.
ABSTRACT Background Plasmodium vivax remains a challenge for malaria elimination in Nepal due to its ability to relapse. Radical cure with primaquine is effective but limited by poor adherence to the standard 14‐day low‐dose regimen. In 2022, the WHO recommended administering the same total dose (3.5 mg/kg) over 7 days to improve adherence.
Prakash Ghimire   +18 more
wiley   +1 more source

Thalassemia carriers exhibit reduced expression of the receptor for the malarial parasite Plasmodium vivax on erythrocytes. [PDF]

open access: yesBlood Adv
Huang R   +10 more
europepmc   +1 more source

A novel immortalized hepatocyte-like cell line (imHC) supports in vitro liver stage development of the human malarial parasite Plasmodium vivax. [PDF]

open access: yesMalar J, 2018
Pewkliang Y   +10 more
europepmc   +1 more source

Role of STAT1 in modulating the host immune response to <i>Plasmodium yoelii</i> 17XL-infected murine blood-stage malaria. [PDF]

open access: yesMicrobiol Spectr
Sun Y   +11 more
europepmc   +1 more source

De novo assembly of the dual transcriptomes of a polymorphic raptor species and its malarial parasite. [PDF]

open access: yesBMC Genomics, 2015
Pauli M   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy